Key result
Cancer and anticancer therapies increase AF and atrial cardiomyopathy risk via inflammation and structural remodeling.
Why the study?
The scarcity of current literature and ambiguous results make the relationship between cancer, atrial cardiomyopathy, and atrial fibrillation difficult to fully understand.
This review summarizes the mechanisms by which cancer and its treatments contribute to atrial remodeling, atrial cardiomyopathy, and atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to AF risk in cancer patients; leaves open prospective validation of screening and prevention strategies.
The number of patients with oncologic and cardiologic comorbidities is increasing. A growing number of evidence shows an inextricable link between cancer, atrial fibrillation, and atrial cardiomyopathy. Cancer itself and resultant inflammation, anticancer treatment, and other comorbidities lead to atrial remodeling and fibrosis, which increases the tendency to develop atrial cardiomyopathy and atrial fibrillation. The scarcity of current literature and ambiguous results make its relationship difficult to fully understand. In this review, we will summarize existing evidence of the relationships and interactions among cancer, atrial cardiomyopathy, and atrial fibrillation and discuss the underlying mechanisms, and provide better information for the management of these patients.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2021) conducted a review in Atrial fibrillation and atrial cardiomyopathy in cancer. Cancer and anticancer treatments was evaluated. Cancer and anticancer treatments predispose patients to an increased risk of atrial fibrillation and atrial cardiomyopathy through systemic inflammation, apoptosis, and structural atrial remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: